RTP Mobile Logo
Dermatologic Oncology Update, Issue 1, 2012
Released June 2012

Featuring interviews with Drs Karl Lewis and Antoni Ribas. (Audio Content)

CE Disclosures and Faculty Information


    Taken together, melanoma and nonmelanoma skin cancer — basal cell and cutaneous squamous cell cancer (BCC and SCC) — likely represent the most prevalent form of human cancer. Fortunately, the vast majority of skin cancers present as minimally invasive BCC and SCC and, as such, are highly curable with local treatment alone. However, in rare instances, these characteristically indolent lesions progress and necessitate systemic intervention with the support of limited randomized clinical evidence. In contrast, malignant melanoma is the most aggressive form of skin cancer with a predilection toward distant metastases, even when identified in the clinically early stages of disease. Thus melanoma and nonmelanoma skin cancer are distinct entities, each posing unique challenges to the oncology community. Featuring information on the latest research developments along with expert perspectives, this CME activity is designed to assist medical oncologists, hematologist-oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.


    • Integrate practice-changing clinical trial results into the treatment algorithm for front-line and subsequent management of advanced melanoma and nonmelanoma skin cancer.
    • Develop evidence-based treatment plans for patients with advanced BRAF V600E mutation-positive and wild-type melanoma.
    • Compare and contrast the patterns of tumor response resulting from melanoma treatment with cytotoxic agents versus kinase inhibitors versus immunotherapeutic agents.
    • Recognize immune-related adverse events associated with anti-CTLA-4 antibody therapy, and offer supportive management strategies to minimize and/or manage these side effects.
    • Identify patients with locally advanced or metastatic BCC for whom Hedgehog inhibitor therapy may be an appropriate treatment option.
    • Counsel appropriately selected patients about participation in ongoing clinical trials.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    This CME activity contains an audio component. The participant should review the CME information and listen to the audio MP3s.

    CME credit is no longer available for this issue


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr LewisAdvisory Committee and Consulting Agreement: Genentech BioOncology; Paid Research: Genentech BioOncology, Novartis Pharmaceuticals Corporation. Dr RibasAdvisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Merck and Company Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc.
    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

    — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation and Genentech BioOncology.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: June 2012
    Expiration date: June 2013

Acknowledge and close

Listen to audio:
Dermatologic Oncology Update, Issue 1, 2012
Released June 2012

Featuring interviews with Drs Karl Lewis and Antoni Ribas. (Audio Content)

Read print: